Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,473
Recruiting: 1,285
Ph III recruiting: 130
Growth YoY: +6.4%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,641)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07348575	A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma	enrolling by invitation	Phase 3	80	Second Affiliated Hospital of Nanchang UniversityOTHER	1	Jan 16, 2026	clinicaltrials
NCT07258680	BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas(BrEto-TCL)	enrolling by invitation	Phase 3	114	N.N. Petrov National Medical Research Center of Oncology